3,938 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Gemmer Asset Management LLC

Gemmer Asset Management LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 3,938 shares of the biopharmaceutical company’s stock, valued at approximately $270,000.

A number of other hedge funds have also recently modified their holdings of the stock. Private Wealth Management Group LLC purchased a new position in Gilead Sciences during the 4th quarter worth $29,000. Sachetta LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $30,000. Palisade Asset Management LLC acquired a new position in Gilead Sciences during the first quarter worth $29,000. Rakuten Securities Inc. acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $33,000. Finally, Gladius Capital Management LP purchased a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $34,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Up 1.4 %

NASDAQ GILD traded up $0.99 during mid-day trading on Tuesday, reaching $73.98. 4,319,014 shares of the company’s stock traded hands, compared to its average volume of 7,365,689. The company has a fifty day simple moving average of $70.00 and a 200-day simple moving average of $70.34. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86. The company has a market cap of $92.17 billion, a price-to-earnings ratio of 202.75, a P/E/G ratio of 3.37 and a beta of 0.18. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 4.16%. The ex-dividend date of this dividend is Friday, September 13th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares in the company, valued at $6,614,559.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on GILD shares. Barclays cut their price objective on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 29th. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 27th. UBS Group dropped their price objective on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Royal Bank of Canada raised their price target on shares of Gilead Sciences from $71.00 to $72.00 and gave the stock a “sector perform” rating in a research note on Friday. Finally, Robert W. Baird reissued a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research report on Thursday, June 20th. Twelve analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $81.88.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.